- Home
- CSTL vs MNMD Comparison
CSTL vs MNMD Comparison
Compare CSTL & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- MNMD
- Stock Information
- Founded
- CSTL 2007
- MNMD 2019
- Country
- CSTL United States
- MNMD United States
- Employees
- CSTL N/A
- MNMD N/A
- Industry
- CSTL Medical Specialities
- MNMD Pharmaceuticals and Biotechnology
- Sector
- CSTL Health Care
- MNMD Health Care
- Exchange
- CSTL Nasdaq
- MNMD Nasdaq
- Market Cap
- CSTL 697.9M
- MNMD 811.9M
- IPO Year
- CSTL 2019
- MNMD N/A
- Fundamental
- Price
- CSTL $22.75
- MNMD $11.91
- Analyst Decision
- CSTL Strong Buy
- MNMD Strong Buy
- Analyst Count
- CSTL 6
- MNMD 6
- Target Price
- CSTL $37.67
- MNMD $26.50
- AVG Volume (30 Days)
- CSTL 348.6K
- MNMD 1.7M
- Earning Date
- CSTL 11-03-2025
- MNMD 11-06-2025
- Dividend Yield
- CSTL N/A
- MNMD N/A
- EPS Growth
- CSTL N/A
- MNMD N/A
- EPS
- CSTL N/A
- MNMD N/A
- Revenue
- CSTL $346,269,000.00
- MNMD N/A
- Revenue This Year
- CSTL N/A
- MNMD N/A
- Revenue Next Year
- CSTL N/A
- MNMD N/A
- P/E Ratio
- CSTL N/A
- MNMD N/A
- Revenue Growth
- CSTL 20.40
- MNMD N/A
- 52 Week Low
- CSTL $14.59
- MNMD $4.70
- 52 Week High
- CSTL $35.84
- MNMD $12.76
- Technical
- Relative Strength Index (RSI)
- CSTL 52.78
- MNMD 64.95
- Support Level
- CSTL $22.28
- MNMD $8.77
- Resistance Level
- CSTL $23.71
- MNMD $12.76
- Average True Range (ATR)
- CSTL 1.05
- MNMD 0.81
- MACD
- CSTL -0.12
- MNMD 0.21
- Stochastic Oscillator
- CSTL 35.90
- MNMD 80.44
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).